<a href="https://www.fiercebiotech.com/biotech/roche-unpacks-death-imbalance-secondary-endpoints-phase-3-multiple-sclerosis-trials" hreflang="en">Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials</a>
Roche has reported an imbalance in fatalities during its phase 3 trials of fenebrutinib for relapsing multiple sclerosis, with eight deaths in the treatment group compared to one in the control, raising safety concerns despite the drug showing significant efficacy in reducing relapse rates and inflammation markers. The company plans to submit trial data to regulators as it anticipates strong market potential for fenebrutinib, amid competition from other BTK inhibitors.
The key insight for you is that Roche plans to submit data on fenebrutinib from their RMS and PPMS trials to regulators despite safety concerns due to imbalanced fatalities. This presents both a potential risk and opportunity for investment, as the drug shows statistical significance in reducing inflammation and chronic disease burden, offering a competitive edge in the RMS market. However, Novartis' BTK inhibitor, with a potentially differentiated safety profile, may pose a challenge, making it crucial to monitor regulatory feedback and competitive developments closely.